Study estimates R&D spending on bringing new cancer drug to market

September 11, 2017, The JAMA Network Journals

Research and development costs are a common justification for high cancer drug prices and a new study published by JAMA Internal Medicine offers an updated estimate of the spending needed to bring a drug to the U.S. market.

Sham Mailankody, M.B.B.S., of the Memorial Sloan Kettering Cancer Center, New York, and coauthors analyzed U.S. Securities and Exchange Commission filings for drug companies with no drugs on the U.S. market that received approval from the U.S. Food and Drug Administration for a cancer drug from 2006 through 2015. The analysis by the authors included 10 companies and drugs. They used a different approach to update previous estimates that had ranged from $320 million to $2.7 billion to develop one new drug.

The authors report:

  • The 10 companies had a median time of 7.3 years to develop a drug.
  • The median cost of drug development was $648 million.
  • The total revenue of these 10 drugs was $67 billion from the time of approval to December 2016 or until the company sold or licensed the compound to another company.
  • The median revenue for these companies in 2017 U.S. dollars was about $1.6 billion and the average was almost $6.7 billion.

The authors acknowledge study limitations, including a small data set. The analysis also pertains only to cancer drugs and cannot be extrapolated to other sectors where drug development can be harder for biological reasons.

"This analysis provides a transparent estimate of R&D spending on cancer drugs and has implications for the current debate on drug pricing," the article concludes.

Explore further: New model mimics human tumors for accurate testing of cancer drugs

More information: JAMA Internal Medicine (2017). doi:10.1001/jamainternmed.2017.3601

Related Stories

New model mimics human tumors for accurate testing of cancer drugs

October 11, 2018
Walter and Eliza Hall Institute researchers have genetically engineered a new laboratory model that enables accurate testing of anti-cancer drugs by mimicking the complexity of human cancers.

'Cutting edge' CAR T cell immunotherapy approved in England. But is the NHS ready?

October 8, 2018
Today, a new blood cancer treatment was approved for use on the NHS in England. And in early September, NHS England announced another, similar treatment will be available to some children and young people with a different ...

Cell therapy, now artisanal and costly, heads for mass production

October 12, 2018
Not so long ago, manipulating living cells to serve as therapies was a difficult and mysterious art. Only a few biomedical companies and academic labs could claim proficiency.

Missouri voters must decide on 3 medical marijuana plans

October 12, 2018
Missouri supporters of medical marijuana will have their say in the November election. The only question: Do they cast a yes vote once, twice or three times?

Analysis: Is 'precision medicine' the answer to cancer? Not precisely

September 21, 2018
Facing incurable breast cancer at age 55, MaryAnne DiCanto put her faith in "precision medicine—in which doctors try to match patients with drugs that target the genetic mutations in their tumors. She underwent repeated ...

Drug prices going up despite Trump promise

September 24, 2018
President Donald Trump made reducing drug prices a key promise during his election campaign, repeatedly accusing drugmakers of "getting away with murder." At the end of May, he promised that drug companies would be announcing ...

Recommended for you

Medicating distress: Risky sedative prescriptions for older adults vary widely

October 18, 2018
Despite years of warnings that older adults shouldn't take sedative drugs that put them at risk of injury and death, a new study reveals how many primary care doctors are still prescribing them, how often, and exactly where.

Medical management of opioid-induced constipation differs from other forms of condition

October 17, 2018
Traditional laxatives are recommended as first-line agents to treat patients with a confirmed diagnosis of opioid-induced constipation (OIC), according to a new guideline from the American Gastroenterological Association ...

Research assesses geographic distribution of new antibiotics following market introduction

October 16, 2018
There is a growing need for new antibiotics to help combat the looming threat of antimicrobial resistance. According to a new study conducted by researchers at the Center for Disease Dynamics, Economics & Policy (CDDEP) with ...

Health insurer policies may discourage use of non-opioid alternatives for lower back pain

October 5, 2018
Public and private health insurance policies in the U.S. are missing important opportunities to encourage the use of physical therapy, psychological counseling and other non-drug alternatives to opioid medication for treating ...

Opioid overdoses, depression linked

October 3, 2018
The link between mental health disorders and substance abuse is well-documented. Nearly one in 12 adults in the U.S is depressed, and opioid-related deaths are skyrocketing. As these numbers continue to climb, some mental ...

Do price spikes on some generic drugs indicate problems in the market?

October 1, 2018
A new USC study reports that sudden price spikes for some generic drugs—such as the recently reported increases of a decades-old generic heart medication and an antibiotic—are becoming more common.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.